Search Results - "Neto, A.E. Hallack"

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide by Castro, T B M, Hallack Neto, A E, Atalla, A, Ribeiro, L C

“…In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a…”
Get full text

Results of CHOP chemotherapy for diffuse large B-cell lymphoma by Hallack Neto, A E, Pereira, J, Beitler, B, Chamone, D A F, Llacer, P D, Dulley, F L, Macedo, M C M A, Chaoubah, A

“…Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM…”
Get full text

PRINCIPAL ACTIONS OF THE MYELODYSPLASTIC SYNDROME HSCT AMERICAN LATIN REGISTRY by Duarte, F.B., Santos, T.E., Funke, V., Colturato, V.A.R., Hamerschlak, N., Villela, N., Macedo, M.C.M.A., Vigorito, A.C., Soares, R.D.A., Paz, A., Diaz, L., Stevenazzi, M., Neto, A.E. Hallack, Bettarello, G., Gusmão, B.M., Salvino, M.A., Calixto, R.F., Moreira, M.C.R., Teixeira, G.M., Silva, C.C., Paton, E.J.A., Rocha, V., Enrico, A., Bonfim, C., Chiattone, R., Simioni, A.J., Arrais, C., Coelho, E.O.D.M.

Get full text

243 - Relevance of Cytogenetics in Myelodysplastic Syndrome (MDS) in the Assessment of Hematopoietic Stem Cell Transplantation (HSCT) Survival by Duarte, F., Santos, T.E.J., Korhnblitt, L., Correa, W., Basquiera, A.L., Belli, C., Funke, V.A.M., Colturato, V.A.R., Hamerschlak, N., Vilela, N.C., Silva, R.L., Vigorito, A.C., Paz, A., Stevenazzi, M., Velloso, E., Neto, A.E. Hallack, Bettarello, G., Lopes, L.F., Soares, R.D.D.A., Lemes, R.P.G.

Get full text

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide by T.B.M. Castro, A.E. Hallack Neto, A. Atalla, L.C. Ribeiro

“…In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a…”
Get full text

Relevance of Cytogenetics in Myelodysplastic Syndrome (MDS) in the Assessment of Hematopoietic Stem Cell Transplantation (HSCT) Survival by Duarte, F, Santos, T.E.J, Korhnblitt, L, Correa, W, Basquiera, A.L, Belli, C, Funke, V.A.M, Colturato, V.A.R, Hamerschlak, N, Vilela, N.C, Silva, R.L, Vigorito, A.C, Paz, A, Stevenazzi, M, Velloso, E, Neto, A.E. Hallack, Bettarello, G, Lopes, L.F, Soares, R.D.D.A, Lemes, R.P.G

Get full text

Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose by dos Santos, K B, Costa, L J, Atalla, A, Pereira, J, Hallack-Neto, A E

Get full text

Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT by Hallack Neto, A E, Dulley, F L, Coelho Siqueira, S A, Pracchia, L F, Belesso, M, Saboya, R, Sturaro, D, Amigo-Filho, J U, Mendrone Junior, A, Chamone, D A F, Pereira, J

“…A total of 53 patients aged 18–60 years with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) were evaluated to analyze the impact of the…”
Get full text

Results of CHOP chemotherapy for diffuse large B-cell lymphoma by Hallack Neto, A.E., Pereira, J., Beitler, B., Chamone, D.A.F., Llacer, P.D., Dulley, F.L., Macedo, M.C.M.A., Chaoubah, A.

Get full text